Phase II study of CDDP/Alimuta combined with bevacizumab in patients with advanced non-small-cell lung cancer without harboring sensitive EGFR mutations
Phase 2
- Conditions
- advanced non-small-cell lung cancer without harboring sensitive EGFR mutations
- Registration Number
- JPRN-UMIN000003645
- Lead Sponsor
- Department of Comprehensive Cancer Therapy, Shinshu Universituy School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1) pulmonary fibrosis on chest radiograph, 2)active infection, 3) severe heart disease, 4) past history of hypersensitivity to drugs, 5) pleural or pericardial effusion that required drainage, 6) brain metastasis or 7) pregnancy. Patients with a concomitant active malignancy were also excluded. Other concomitant anticancer therapy or experimental drug administration of any type was not permitted.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method